PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34102280-0	2021	Iminodibenzyl redirected cyclooxygenase-2 catalyzed dihomo-gamma-linolenic acid peroxidation pattern in lung cancer.	dibenzylamine	0-13	prostaglandin-endoperoxide synthase 2	Mus musculus	25-41	
34102280-0	2021	Iminodibenzyl redirected cyclooxygenase-2 catalyzed dihomo-gamma-linolenic acid peroxidation pattern in lung cancer.	8,11,14-Eicosatrienoic Acid	52-79	prostaglandin-endoperoxide synthase 2	Mus musculus	25-41	
34102280-2	2021	The rationale of the COX-2 inhibitor lies in suppressing COX-2 catalyzed peroxidation of omega-6 polyunsaturated fatty acids (PUFAs), which are essential and pervasive in our daily diet.	omega-6 polyunsaturated fatty acids	89-124	prostaglandin-endoperoxide synthase 2	Mus musculus	21-26	
34102280-2	2021	The rationale of the COX-2 inhibitor lies in suppressing COX-2 catalyzed peroxidation of omega-6 polyunsaturated fatty acids (PUFAs), which are essential and pervasive in our daily diet.	omega-6 polyunsaturated fatty acids	89-124	prostaglandin-endoperoxide synthase 2	Mus musculus	57-62	
34102280-2	2021	The rationale of the COX-2 inhibitor lies in suppressing COX-2 catalyzed peroxidation of omega-6 polyunsaturated fatty acids (PUFAs), which are essential and pervasive in our daily diet.	Fatty Acids, Unsaturated	126-131	prostaglandin-endoperoxide synthase 2	Mus musculus	21-26	
34102280-2	2021	The rationale of the COX-2 inhibitor lies in suppressing COX-2 catalyzed peroxidation of omega-6 polyunsaturated fatty acids (PUFAs), which are essential and pervasive in our daily diet.	Fatty Acids, Unsaturated	126-131	prostaglandin-endoperoxide synthase 2	Mus musculus	57-62	
34102280-4	2021	Here, instead of directly inhibiting COX-2, we utilize a small molecule, iminodibenzyl, which could reprogram the COX-2 catalyzed omega-6 PUFAs peroxidation in lung cancer by inhibiting delta-5-desaturase (D5D) activity.	dibenzylamine	73-86	prostaglandin-endoperoxide synthase 2	Mus musculus	37-42	
34102280-4	2021	Here, instead of directly inhibiting COX-2, we utilize a small molecule, iminodibenzyl, which could reprogram the COX-2 catalyzed omega-6 PUFAs peroxidation in lung cancer by inhibiting delta-5-desaturase (D5D) activity.	dibenzylamine	73-86	prostaglandin-endoperoxide synthase 2	Mus musculus	114-119	
34102280-4	2021	Here, instead of directly inhibiting COX-2, we utilize a small molecule, iminodibenzyl, which could reprogram the COX-2 catalyzed omega-6 PUFAs peroxidation in lung cancer by inhibiting delta-5-desaturase (D5D) activity.	dibenzylamine	73-86	fatty acid desaturase 1	Mus musculus	186-204	
34102280-4	2021	Here, instead of directly inhibiting COX-2, we utilize a small molecule, iminodibenzyl, which could reprogram the COX-2 catalyzed omega-6 PUFAs peroxidation in lung cancer by inhibiting delta-5-desaturase (D5D) activity.	omega-6 pufas	130-143	prostaglandin-endoperoxide synthase 2	Mus musculus	37-42	
34102280-4	2021	Here, instead of directly inhibiting COX-2, we utilize a small molecule, iminodibenzyl, which could reprogram the COX-2 catalyzed omega-6 PUFAs peroxidation in lung cancer by inhibiting delta-5-desaturase (D5D) activity.	omega-6 pufas	130-143	prostaglandin-endoperoxide synthase 2	Mus musculus	114-119	
34102280-4	2021	Here, instead of directly inhibiting COX-2, we utilize a small molecule, iminodibenzyl, which could reprogram the COX-2 catalyzed omega-6 PUFAs peroxidation in lung cancer by inhibiting delta-5-desaturase (D5D) activity.	omega-6 pufas	130-143	fatty acid desaturase 1	Mus musculus	186-204	
34102280-6	2021	By utilizing COX-2 overexpression in cancer, the combination of DGLA supplementation and iminodibenzyl suppressed YAP1/TAZ pathway, decreasing the tumor size and lung metastasis in nude mice and C57BL/6 mice.	8,11,14-Eicosatrienoic Acid	64-68	prostaglandin-endoperoxide synthase 2	Mus musculus	13-18	
34102280-6	2021	By utilizing COX-2 overexpression in cancer, the combination of DGLA supplementation and iminodibenzyl suppressed YAP1/TAZ pathway, decreasing the tumor size and lung metastasis in nude mice and C57BL/6 mice.	8,11,14-Eicosatrienoic Acid	64-68	yes-associated protein 1	Mus musculus	114-118	
34102280-6	2021	By utilizing COX-2 overexpression in cancer, the combination of DGLA supplementation and iminodibenzyl suppressed YAP1/TAZ pathway, decreasing the tumor size and lung metastasis in nude mice and C57BL/6 mice.	8,11,14-Eicosatrienoic Acid	64-68	tafazzin, phospholipid-lysophospholipid transacylase	Mus musculus	119-122	
34102280-6	2021	By utilizing COX-2 overexpression in cancer, the combination of DGLA supplementation and iminodibenzyl suppressed YAP1/TAZ pathway, decreasing the tumor size and lung metastasis in nude mice and C57BL/6 mice.	dibenzylamine	89-102	prostaglandin-endoperoxide synthase 2	Mus musculus	13-18	
34102280-6	2021	By utilizing COX-2 overexpression in cancer, the combination of DGLA supplementation and iminodibenzyl suppressed YAP1/TAZ pathway, decreasing the tumor size and lung metastasis in nude mice and C57BL/6 mice.	dibenzylamine	89-102	yes-associated protein 1	Mus musculus	114-118	
34102280-6	2021	By utilizing COX-2 overexpression in cancer, the combination of DGLA supplementation and iminodibenzyl suppressed YAP1/TAZ pathway, decreasing the tumor size and lung metastasis in nude mice and C57BL/6 mice.	dibenzylamine	89-102	tafazzin, phospholipid-lysophospholipid transacylase	Mus musculus	119-122